Tianda Pharmaceuticals Ltd (0455) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Tianda Pharmaceuticals Ltd stock HK$0.06, price HK$0.07, that is 11.1% below the price, quality 45 out of 100. Rating: overvalued. Calculated from audited financials with 5 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range HK$0.0720 – HK$0.4054 · fair‑value band HK$0.0480 – HK$0.0880 · the HK$0.0720 price screens above the HK$0.0640 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Tianda Pharmaceuticals in your weekly email
Every Wednesday you see whether Tianda Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tianda Pharmaceuticals Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.
Show moreShow less
It operates through the Chinese Medicine; Pharmaceuticals and Medical Technologies; and Medical and Healthcare Services segments. The company offers Chinese herbal medicine, Chinese medicine decoction pieces, Chinese medicine products, and Chinese medicine clinical services.
It also produces pharmaceutical products focusing on cardiovascular and cerebrovascular medication, respiratory infections, and pediatric diseases. In addition, the company trades agricultural by-products.
The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.
Stock analysis
Tianda Pharmaceuticals Ltd (0455) currently trades at HK$0.0720, while our model-based Fair Value estimate is HK$0.0640, 11% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of HK$0.1000 per share, and 1 of the 5 models we run sit above the HK$0.0720 price.
Bear case: the DCF Models group reads lowest at HK$0.0400, and 4 of the 5 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.0480 (bear) to HK$0.0880 (bull), the price of HK$0.0720 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2003: revenue and profit before it include the divested business. Growth is measured afresh from 2003.
Tianda Pharmaceuticals Ltd reported revenue of HK$323M in FY2026 versus HK$510M in FY2022, a compound −10.8%/yr. Reported net income was −HK$70.0M in FY2026.
Key figures
Market cap HK$155M (≈ $19.7M) Micro · P/S ratio 0.55 · Dividend yield 2.9% · Net margin −21.7% · Return on equity −14.9% · Return on assets (EBIT) −5.5% (5-year average) · Operating margin −18.1% · Revenue (TTM) HK$351M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 48% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −11%, 0455 screens cheaper than that median.
Fair Value models
BearHK$0.0480Fair Value HK$0.0640BullHK$0.0880
Price HK$0.0720 · Downside -11.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2003: revenue and profit before it include the divested business. Growth is measured afresh from 2003.
Revenue growth 1 year
−2.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.4%
Start year 2021 (pandemic). Over 10 years: +5.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5.6% (2021) → −16.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+37.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +34.5% a year for the price.
Compare Tianda Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−11.1% · Above median
Profitability
Return on assets−9.4% · Bottom 25%
Net margin (12 months)−19.7% · Bottom 25%
Operating margin (12 months)−18.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)20.2% · Top 25%
Dividend yield (12 months)2.9% · Above median
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tianda Pharmaceuticals Ltd (0455) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of HK$0.0640 versus a price of HK$0.0720, about 11% lower (overvalued).
What is the fair value of 0455?
Our model-based fair value for Tianda Pharmaceuticals Ltd is HK$0.0640 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.0720.
What is the quality score of 0455?
Tianda Pharmaceuticals Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tianda Pharmaceuticals Ltd (0455)?
Our model-based price target is the fair value of HK$0.0640 (as of Nov 10, 2026) from 5 valuation models. Cautious scenario HK$0.0480, optimistic scenario HK$0.0880. It is a calculation from audited fundamentals, not an analyst target.
What is the Tianda Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at HK$0.0640, about 11% lower versus a price of HK$0.0720 (overvalued). Cautious scenario HK$0.0480, optimistic scenario HK$0.0880. The calculation is refreshed regularly with new filings.
What is the revenue of Tianda Pharmaceuticals Ltd (0455)?
Tianda Pharmaceuticals Ltd reported trailing-twelve-month revenue of about HK$351M (latest available figure, as of Nov 10, 2026).
Does Tianda Pharmaceuticals Ltd pay a dividend?
Tianda Pharmaceuticals Ltd currently shows a dividend yield of 2.92% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Tianda Pharmaceuticals Ltd (0455)?
Tianda Pharmaceuticals Ltd has a dividend yield of 2.9%.
What growth is priced into Tianda Pharmaceuticals Ltd (0455)?
For today's price to be fair in a discounted-cash-flow model, Tianda Pharmaceuticals Ltd would have to grow free cash flow by +37.3 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -7.4 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of 0455 use?
Our models discount Tianda Pharmaceuticals Ltd at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tianda Pharmaceuticals Ltd that is +37.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Tianda Pharmaceuticals Ltd (0455) delivered so far?
Over the past 5 years revenue at Tianda Pharmaceuticals Ltd grew -7.4 % a year. The price currently implies free-cash-flow growth of +37.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tianda Pharmaceuticals Ltd (0455) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into Tianda Pharmaceuticals Ltd (+37.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tianda Pharmaceuticals Ltd (0455)?
The free-cash-flow yield on the price is 1.81 %: that much free cash flow Tianda Pharmaceuticals Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tianda Pharmaceuticals Ltd (0455)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tianda Pharmaceuticals Ltd it is HK$0.0640 per share (as of Nov 10, 2026), against a price of HK$0.0720. It is the blended result of 5 valuation models in 3 families (DCF Models, Asset-Based, Growth DCF).
Is Tianda Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 0455 trades above its calculated fair value: price HK$0.0720, fair value HK$0.0640, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0455?
No. The price is what the market pays today (HK$0.0720); the fair value is what the company's own numbers justify (HK$0.0640). For Tianda Pharmaceuticals Ltd the two are HK$0.0080 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tianda Pharmaceuticals Ltd worth?
The market values Tianda Pharmaceuticals Ltd at about HK$155M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.0720; our models calculate a fair value of HK$0.0640 per share.
What do the bullish and bearish scenarios say about 0455?
Our models span a range for Tianda Pharmaceuticals Ltd: cautious scenario HK$0.0480, base HK$0.0640, optimistic HK$0.0880 per share (as of Nov 10, 2026, price HK$0.0720). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tianda Pharmaceuticals Ltd (0455)?
Balance-sheet figures for Tianda Pharmaceuticals Ltd (as of Nov 10, 2026): return on equity −14.9%, debt of 0.09 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 0455 from its 52-week high?
Tianda Pharmaceuticals Ltd trades at HK$0.0720, about 48% below its 52-week high of HK$0.1390 and at the low of HK$0.0720 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0640 is for.
Which stocks are comparable to Tianda Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tianda Pharmaceuticals Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.0720, calculated fair value HK$0.0640 (−11%), Quality Score 45/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0455 calculated?
We run Tianda Pharmaceuticals Ltd through 5 models from 3 families: DCF Models, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of HK$0.0640 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Tianda Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tianda Pharmaceuticals Ltd (0455)?
The closing price on Nov 13, 2026 was HK$0.0720. Our model-based fair value is HK$0.0640, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tianda Pharmaceuticals Ltd right now?
A fairly wide model range (HK$0.0480 to HK$0.0880) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Tianda Pharmaceuticals Ltd
How large is the market capitalisation of Tianda Pharmaceuticals Ltd (0455)?
The market capitalisation of Tianda Pharmaceuticals Ltd is HK$155M (≈ $19.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tianda Pharmaceuticals Ltd (0455)?
The price-to-sales ratio of Tianda Pharmaceuticals Ltd is 0.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Tianda Pharmaceuticals Ltd (0455)?
The dividend yield of Tianda Pharmaceuticals Ltd is 2.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tianda Pharmaceuticals Ltd (0455)?
The net margin of Tianda Pharmaceuticals Ltd is −21.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tianda Pharmaceuticals Ltd (0455)?
The return on equity (ROE) of Tianda Pharmaceuticals Ltd is −14.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tianda Pharmaceuticals Ltd (0455)?
On an EBIT basis the return on assets of Tianda Pharmaceuticals Ltd is −5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tianda Pharmaceuticals Ltd (0455)?
The operating margin of Tianda Pharmaceuticals Ltd is −18.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tianda Pharmaceuticals Ltd (0455)?
Revenue at Tianda Pharmaceuticals Ltd is growing +20.2% versus a year earlier (3y avg −16.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tianda Pharmaceuticals Ltd (0455)?
Earnings per share at Tianda Pharmaceuticals Ltd are growing +244% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Tianda Pharmaceuticals Ltd (0455) carry?
The net debt of Tianda Pharmaceuticals Ltd is HK$67.9M (fiscal year 2026, ≈ 24.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tianda Pharmaceuticals Ltd in the live analysis
One click puts Tianda Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026